Once the capacity of 4PD to bind and transfect myeloid cells in vivo with multiple shRNAs was determined, we evaluated the effect of chronic CCR1, CCR2, CCR5, and CCR7 silencing on tumor progression. Here, CCR2 is linked to neoplasm.